Masimo Corporation $MASI Shares Bought by Cwm LLC

Key Points

• Cwm LLC boosted its stake in Masimo by 2,045.3% in Q4, adding 17,671 shares to hold 18,535 shares worth about $2.41 million according to its latest 13F filing.
• Several research firms have recently downgraded MASI, leaving eight "Hold" and one "Sell" ratings; MarketBeat's consensus rating is Reduce with an average price target of $181.17.
• Masimo trades near $178.63 with a market capitalization of $9.59 billion, a negative P/E of -16.95, and a 52‑week range of $125.94–$179.00, signaling mixed valuation and profitability metrics.

Cwm LLC boosted its stake in shares of Masimo Corporation (NASDAQ:MASI - Free Report) by 2,045.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,535 shares of the medical equipment provider's stock after acquiring an additional 17,671 shares during the quarter. Cwm LLC's holdings in Masimo were worth $2,411,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC lifted its position in Masimo by 99.6% during the 4th quarter. Farther Finance Advisors LLC now owns 2,144 shares of the medical equipment provider's stock worth $279,000 after acquiring an additional 1,070 shares during the period. Assetmark Inc. increased its stake in Masimo by 5.5% in the 4th quarter. Assetmark Inc. now owns 1,850 shares of the medical equipment provider's stock valued at $241,000 after buying an additional 97 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Masimo by 1.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 2,663,875 shares of the medical equipment provider's stock valued at $346,464,000 after buying an additional 43,915 shares during the period. Exchange Traded Concepts LLC increased its stake in Masimo by 17.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,101 shares of the medical equipment provider's stock valued at $663,000 after buying an additional 772 shares during the period. Finally, Orser Capital Management LLC acquired a new position in Masimo in the 4th quarter valued at $319,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MASI has been the topic of several recent research reports. Raymond James Financial cut shares of Masimo from an "outperform" rating to a "market perform" rating in a research note on Friday, March 27th. Wolfe Research downgraded shares of Masimo from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 19th. Piper Sandler downgraded shares of Masimo from an "overweight" rating to a "hold" rating and set a $180.00 price objective for the company. in a research report on Tuesday, February 17th. Weiss Ratings restated a "sell (d)" rating on shares of Masimo in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus set a $180.00 price objective on shares of Masimo in a research report on Tuesday, February 17th. Eight equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $181.17.

Masimo Stock Down 0.0%

Shares of NASDAQ MASI opened at $178.63 on Friday. The company has a quick ratio of 1.47, a current ratio of 2.49 and a debt-to-equity ratio of 0.72. Masimo Corporation has a 52 week low of $125.94 and a 52 week high of $179.00. The firm has a 50-day moving average price of $176.05 and a 200 day moving average price of $153.09. The stock has a market capitalization of $9.59 billion, a price-to-earnings ratio of -16.95, a price-to-earnings-growth ratio of 1.81 and a beta of 1.20.

Masimo Profile

Masimo NASDAQ: MASI is a global medical technology company specializing in noninvasive monitoring solutions. The company's flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo's portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.